Caladrius Biosciences to Halt Phase 3 Study of CLBS20

Caladrius Biosciences will discontinue a Phase 3 study of CLBS20 as a monotherapy for treatment of recurrent Stage III or IV metastatic melanoma.

Company CEO David Mazzo says the decision is based on the accelerating adoption of alternative treatments that have improved outcomes in metastatic melanoma. However, the company will examine the potential of a partnership using the candidate as part of a combination therapy.